Publication number: 20220339291
Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting DLK1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically, uses for such ADCs in producing drugs for treatment and/or prevention of proliferative and/or angiogenetic diseases, for example, cancer. More particularly, the present invention relates to an antibody-drug conjugate comprising an antibody binding with DLK1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
Type:
Application
Filed:
March 5, 2020
Publication date:
October 27, 2022
Inventors:
Chang Sik Park, Min Ji Choi, Tae Ik Jang, Yun-Hee Park, Ho Young Song, Ju Yuel Baek, Sung Min Kim, Hyeun Joung Lee, Ju Young Lee, Hyoung Rae Kim, Kun Jung Lee, Yong Zu Kim, Chang Sun Lee, Jeiwook Chae, Sang Pil Lee, Ji-Young Shin, Sunha Yoon, Yunseon Choi, Jae Eun Park, Jisu Lee, Bum-Chan Park, Young Woo Park